Defending TrumpRx Scam, RFK Jr. Absurdly Claims Trump ‘Has His Own Way of Calculating’ Percentages

Key Takeaways

• TrumpRx lists brand-name drugs at prices far above generic equivalents
• Kennedy defended Trump's 600% price‑cut claim, misusing percentage math
• Senators Warren and Sanders highlighted minimal genuine discounts on TrumpRx
• CAP report found only 1 of 54 TrumpRx drugs offered true savings

Pulse Analysis

The TrumpRx controversy erupted when HHS Secretary Robert F. Kennedy Jr. attempted to rationalize President Trump’s claim of a 600% price reduction on prescription drugs. By redefining percentage calculations, Kennedy not only displayed a basic mathematical error but also lent credibility to a narrative that suggests consumers are paying far less than they actually are. This misrepresentation was quickly challenged on the Senate Finance Committee, where lawmakers emphasized that a 600% reduction would imply manufacturers paying customers, a scenario that defies economic reality.

Beyond the arithmetic slip, the hearing revealed substantive pricing discrepancies on the TrumpRx platform. Investigations by Senators Warren and Sanders showed that the site lists brand‑name drugs at prices dramatically higher than readily available generics—$200 for a heartburn medication versus $16 at Costco, for example. Moreover, the administration’s tariff exemptions for participating pharmaceutical firms create a perverse incentive: companies gain financial relief without passing savings to patients. This dynamic reinforces the perception that the policy benefits Big Pharma more than consumers, eroding public trust in government‑led pricing initiatives.

The episode arrives amid broader concerns about rising drug costs, with Reuters reporting over 350 branded medications slated for price hikes in 2026, including vaccines and cancer therapies. The limited genuine discounts on TrumpRx, confirmed by the Center for American Progress, suggest that the administration’s approach may lack the rigor needed to curb escalating expenses. Policymakers and industry observers are now calling for greater transparency, stricter oversight, and alternative pricing strategies to ensure that any future reforms deliver real savings to American patients.